Amylyx Pharmaceuticals planira podnošenje propisa AMX0035 za liječenje ALS-a u Kanadi
-
Marketinška prijava u Kanadi (nova prijava lijekova) planirana za prvu polovicu 2021.
-
Amylyx također planira potražiti mogućnosti ranog pristupa u Kanadi
9. ožujka 2021. 08:00 po istočnom standardnom vremenu
CAMBRIDGE, Massachusetts - (
POSLOVNA ŽICA) - Amylyx Pharmaceuticals, Inc., farmaceutska tvrtka usmjerena na razvoj novih tretmana za amiotrofičnu lateralnu sklerozu (ALS), Alzheimerovu bolest i druge neurodegenerativne bolesti, danas je najavila planove za podnošenje nove prijave lijekova (NDS) za AMX0035 za liječenje ALS-a s Health Canadaom u prvoj polovici 2021. Odluka o podnošenju temelji se na pozitivnim kliničkim podacima ispitivanja CENTAUR i povratnim informacijama Health Canadaa. Osim toga, Amylyx će istražiti mogućnosti za rani pristup AMX0035 u Kanadi, uključujući potencijalni program posebnog pristupa (SAP) u suradnji s kanadskom istraživačkom mrežom ALS, a cilj mu je finalizirati planove do kraja drugog tromjesečja 2021. godine.
"Dvije stvari koje najviše cijenimo u Amylyxu su transparentnost i usmjerenost na pacijenta"
Tweet ovo
"Rezultati CENTAUR-a pokazali su da AMX0035 ima i funkcionalne i dugoročne prednosti preživljavanja, što se vidjelo povrh početne primjene odobrenih terapija ALS-om", rekla je dr. Sc. Sabrina Paganoni, glavna istražiteljica ispitivanja CENTAUR, istražiteljica na Sean M. Healey & AMG Centar za ALS u općoj bolnici u Massachusettsu i docent PM&R-a na Medicinskom fakultetu Harvard i bolnici za rehabilitaciju Spaulding. "Budući da je ALS ozbiljna bolest koja brzo napreduje, ovo ispitivanje pruža važne informacije u potrazi za ljudima koji žive s ALS-om koji mogu pružiti održiv tretman - i nadu"
"Two of the things we value most at Amylyx are transparency and patient-centricity,” said Joshua Cohen, Co-CEO, Chairman and Co-Founder of Amylyx. “In that spirit, we are pleased to announce our plans to submit for review and to pursue early access options in Canada and will work to submit the NDS as swiftly as possible because we know that every day matters to people with ALS and their families." Justin Klee, Co-CEO and Co-Founder of Amylyx, added, "Thank you to the entire ALS community who has helped bring this forward; your partnership is paramount. We will keep everyone closely informed as we proceed."
CENTAUR was a 24-week placebo-controlled study of 137 participants with ALS that evaluated the safety and efficacy of AMX0035. As
previously reported, the study met its primary efficacy endpoint of slowing ALS as measured by the ALS Functional Rating Scale-Revised (ALSFRS-R). Similar rates of adverse events were seen in the AMX0035 and placebo arms.
Participants who completed CENTAUR were eligible to enroll in an open-label extension (OLE) and receive AMX0035. In a nearly three-year
overall survival analysis of all randomized participants from CENTAUR, those originally randomized to AMX0035 had a 44% lower risk of death compared to those originally randomized to placebo.
“The CENTAUR clinical trial was led by the Healey & AMG Center at Mass General Hospital with participants enrolled at centers that are part of the Northeast ALS Consortium. ALS Finding a Cure and the ALS Association provided key support. This trial is the best example of how close partnership between people living with ALS, ALS physicians and scientists, trial networks, foundations and pharma can accelerate progress to develop potentially effective and safe treatments,” said Merit Cudkowicz, MD, co-principal investigator of the CENTAUR trial, Director of the Healey & AMG Center for ALS and Chair of Neurology at Massachusetts General Hospital and the Julieanne Dorn Professor of Neurology at Harvard Medical School.
“These positive clinical trial results are encouraging for the approximately 3,000 Canadians living with ALS and their families who are desperately looking for effective treatment options,” said Angela Genge, M.D., Director of the Clinical Research Unit at the Montreal Neurological Institute in Quebec.
“Amylyx’s decision to pursue regulatory approval and a special access program is a promising milestone for the Canadian ALS community,” said Tammy Moore, CEO, ALS Society of Canada. “There is an urgent need for people living with ALS to have access to proven, effective therapies and we hope to see the momentum continue in meaningful ways that will make a difference to Canadians living with the disease.”
In addition to the planned submission in Canada, Amylyx continues to discuss AMX0035 with health authorities around the world to determine the most appropriate path forward in each territory. Amylyx will update the community as soon as possible.
About Amylyx Pharmaceuticals
Amylyx Pharmaceuticals, Inc. is a pharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis (ALS), Alzheimer’s disease and other neurodegenerative diseases. For more information, visit
www.amylyx.com and follow us on
LinkedIn and
Twitter.